Nuclea obtains $1 million in equity funding round

02/22/2013 | American City Business Journals

Nuclea Biotechnologies has secured $1 million in a round of equity financing from 10 investors. The Pittsfield, Mass.-based company focuses on the commercialization of cancer and diabetes diagnostic tests, including a blood-based assay that CEO Patrick Muraca said has been clinically tested for monitoring prostate cancer and other uses.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC